Page 43 - குறிப்பு தொடர்பாக முன்னோக்கி பார்க்கிறது News Today : Breaking News, Live Updates & Top Stories | Vimarsana

EQS-News: PJSC Mechel: Mechel Announces the 1Q 2021 Financial Results Release Date

EQS-News: PJSC Mechel: Mechel Announces the 1Q 2021 Financial Results Release Date PJSC Mechel: Mechel Announces the 1Q 2021 Financial Results Release Date 19.05.2021 / 10:30 MSK MECHEL ANNOUNCES THE 1Q 2021 FINANCIAL RESULTS RELEASE DATE Moscow, Russia - May 19, 2021 - Mechel PAO (MOEX: MTLR, NYSE: MTL), one of the leading Russian mining and metals companies, announces that it intends to release its operational and financial results for the first quarter period ending March 31, 2021, on Thursday, May 20, 2021. e-mail: alexey.lukashov@mechel.com Mechel is an international mining and steel company. Its products are marketed in Europe, Asia, North and South America, Africa. Mechel unites producers of coal, iron ore concentrate, steel, rolled products, ferroalloys, heat and electric power. All of its enterprises work in a single production chain, from raw materials to high value-added products.

United statesAlexey lukashovExchange commissionForeign exchangeNews serviceDistribution servicesQuarter resultsMechel announcesResults release dateSouth americaSecurities litigation reform actNote regarding forward lookingCorporate newsRegulatory announcementsஒன்றுபட்டது மாநிலங்களில்பரிமாற்றம் தரகு

EQS-News: PJSC Mechel : Mechel Announces the 1Q 2021 Financial Results Release Date

EQS-News: PJSC Mechel : Mechel Announces the 1Q 2021 Financial Results Release Date vom 19.05.2021, 09:30 Uhr Bild: pixabay.com PJSC Mechel : Mechel Announces the 1Q 2021 Financial Results Release Date 19.05.2021 / 10:30 MSK MECHEL ANNOUNCES THE 1Q 2021 FINANCIAL RESULTS RELEASE DATE Moscow, Russia - May 19, 2021 - Mechel PAO (MOEX: MTLR, NYSE: MTL), one of the leading Russian mining and metals companies, announces that it intends to release its operational and financial results for the first quarter period ending March 31, 2021, on Thursday, May 20, 2021. e-mail: alexey.lukashov@mechel.com Mechel is an international mining and steel company. Its products are marketed in Europe, Asia, North and South America, Africa. Mechel unites producers of coal, iron ore concentrate, steel, rolled products, ferroalloys, heat and electric power. All of its enterprises work in a single production chain, from raw materials to high value-added products.

United statesAlexey lukashovExchange commissionForeign exchangeNews serviceDistribution servicesQuarter resultsMechel announcesResults release dateSouth americaSecurities litigation reform actNote regarding forward lookingCorporate newsRegulatory announcementsஒன்றுபட்டது மாநிலங்களில்பரிமாற்றம் தரகு

Take-Two Interactive Software, Inc Reports Strong Results for Fiscal Year 2021 – Consumer Electronics Net

Take-Two Interactive Software, Inc Reports Strong Results for Fiscal Year 2021 – Consumer Electronics Net
consumerelectronicsnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from consumerelectronicsnet.com Daily Mail and Mail on Sunday newspapers.

Republic ofUnited kingdomCity ofSteve austinAlan lewisRicky steamboatStrauss zelnickTiger woodsRey mysterioMaibatsu manchez scoutNicole shevinsLaser leagueCorporate communications public affairsObsidian entertainmentHb studios multimedia ltdGolf club

IMBRUVICA® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control

Share this article Share this article RARITAN, N.J., May 19, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study, showing that 95 percent of patients treated with combined IMBRUVICA ® plus venetoclax were alive and progression-free at two years. 1 Deep remissions were seen across all subgroups, including patients with high-risk chronic lymphocytic leukemia (CLL). 1 In addition, long-term data from the RESONATE-2 (PCYC-1115/1116) study will be presented, providing the longest follow-up Phase 3 data for any BTK inhibitor to date. These data reinforce the long-term survival benefits and well-established safety profile of single-agent IMBRUVICA

United statesCraig tendlerJennifer mcintyrePaolo ghiaChristopher deloreficeBernadette kingChristie corbettNone of the janssen pharmaceutical companiesGlobal medical affairsJanssen biotech incAmerican society of clinical oncologyDrug administrationJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonExchange commission

Janssen: IMBRUVICA (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukaemia Demonstrates High Rates of Disease Control

Janssen: IMBRUVICA (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukaemia Demonstrates High Rates of Disease Control
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesCraig tendlerNoah reymondJennifer mcintyrePaolo ghiaChristopher deloreficeEdmond chanGlobal medical affairsJanssen biotech incAmerican society of clinical oncologyEuropean hematology associationJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonAmerican society of hematologyAmerican society of clinical oncology annual meeting